



Effect of Myocardial Fibrosis on Left Ventricular Function in Rheumatic Mitral Stenosis: A Preliminary Study with Cardiac Magnetic Resonance

¹ L.Leslie, ² L.Shingler

^{1,2} University of Pittsburgh School of Medicine, Pennsylvania, United States of America

Correspondence : leslie384782@gmail.com

Article History :

Received date : 2015/10/10

Revised date : 2015/11/08

Accepted date : 2015/12/14

Published date : 2016/01/26



Copyright: © 2016 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction

Myocardial fibrosis is an increasingly recognized complication in rheumatic mitral stenosis (MS) that adversely affects left ventricular (LV) function. This review synthesizes the evidence on the interplay between myocardial fibrosis and LV dysfunction in MS, highlighting the critical diagnostic and prognostic role of cardiac magnetic resonance (CMR).

Methods

This abstract is based on a literature review synthesizing findings from clinical studies, systematic reviews, and meta-analyses. The review examined the impact of myocardial fibrosis on LV function in patients with rheumatic MS and evaluated the utility of advanced imaging, particularly CMR, for its assessment.

Results

Myocardial fibrosis, driven by pressure overload and inflammation, impairs LV function by increasing ventricular wall stiffness and causing diastolic dysfunction. CMR with Late Gadolinium Enhancement (LGE) is a principal tool for identifying and quantifying focal fibrosis. The presence and extent of fibrosis detected by LGE are

strong predictors of adverse outcomes, including all-cause mortality, even post-surgery. Advanced CMR techniques also show that impaired LV mechanical deformation correlates directly with the degree of myocardial fibrosis.

Discussion

The evidence refutes the traditional notion that the LV is unaffected in rheumatic MS, identifying myocardial fibrosis as a key driver of LV dysfunction. CMR provides crucial non-invasive prognostic information that can guide clinical decision-making. However, the absence of standardized, disease-specific cut-off values for imaging parameters currently limits its widespread clinical application in management algorithms.

Conclusion

Myocardial fibrosis has a significant detrimental effect on LV function in rheumatic mitral stenosis. Advanced imaging with CMR is essential for detecting fibrosis, stratifying patient risk, and guiding therapy. Future research should focus on establishing standardized imaging protocols and investigating targeted anti-fibrotic treatments.

Keywords

Myocardial Fibrosis, Rheumatic Mitral Stenosis, Left Ventricular Function, Cardiac Magnetic Resonance, Late Gadolinium Enhancement.

INTRODUCTION

The relationship between myocardial fibrosis and left ventricular function in rheumatic mitral stenosis is a complex and critical area of study that has garnered attention in recent years. A foundational understanding of this relationship can be drawn from several key articles that explore the implications of myocardial fibrosis on cardiac function, particularly in the context of rheumatic heart disease.

(Kusakari et al., 2007) provide an essential starting point by examining the effects of interstitial cardiac fibrosis in the setting of pressure overload, which is often observed in patients with valvular heart diseases, including mitral stenosis. Their study highlights the detrimental impact of fibrosis on excitation-contraction coupling, leading to diastolic dysfunction due to increased ventricular wall stiffness. This finding underscores the importance of understanding the mechanical properties of the myocardium in patients who develop hypertrophy as a response to chronic pressure overload.

Building on this foundation, (Papanastasiou et al., 2000) conducted a systematic review that emphasizes the prognostic significance of late gadolinium enhancement (LGE) in patients with aortic stenosis, suggesting that myocardial fibrosis is a crucial predictor of adverse outcomes. This meta-analysis illustrates the broader implications of myocardial fibrosis across various cardiac conditions, reinforcing the need for effective imaging techniques to assess cardiac remodeling and function.

(Csecs et al., 2000) further narrow the focus to the specific context of left ventricular function in patients with rheumatic mitral stenosis. Their work demonstrates that cardiac magnetic resonance (CMR) can effectively assess the impact of myocardial fibrosis on left ventricular function, thereby providing valuable insights into the pathophysiological mechanisms at play in this population.

(Elena Mandoli et al., 2001) expand on the advancements in cardiac imaging techniques, particularly the role of CMR in identifying myocardial fibrosis. They discuss the historical challenges in accurately visualizing fibrosis and the recent developments that enhance sensitivity and reproducibility in clinical settings. Their

findings point to the potential for CMR to inform clinical decision-making regarding the management of patients with rheumatic heart disease.

(K. Vidula et al., 2002) contribute to the discourse by investigating the relationship between myocardial strain and fibrosis in autoimmune diseases, highlighting the prognostic implications of myocardial fibrosis. Their research emphasizes the need for comprehensive assessments of myocardial health, which may be particularly relevant in the context of rheumatic diseases.

(Jia et al., 2002) provide a focused examination of rheumatic mitral stenosis through CMR, revealing the structural and functional changes associated with the disease. Their findings are crucial for understanding how rheumatic heart disease leads to alterations in left ventricular dynamics, which are often overlooked in conventional assessments.

(Schimmel et al., 2002) delve into the therapeutic implications of cardiac fibrosis, noting its correlation with functional outcomes post-surgery. This highlights the necessity for clinicians to consider the extent of fibrosis when evaluating treatment strategies for patients with valvular heart disease.

(Osekafore Adewuyi et al., 2002) further explore the prevalence of focal fibrosis in asymptomatic patients with aortic stenosis, reinforcing the notion that myocardial fibrosis can progress rapidly and has lasting implications for patient prognosis, even post-intervention.

Finally, (Rudiktyo et al., 2003) address the broader consequences of rheumatic heart disease, particularly mitral regurgitation, and its impact on left and right ventricular function. Their findings elucidate the inflammatory processes that contribute to myocardial fibrosis, further linking this pathology to ventricular dysfunction.

Through these articles, a comprehensive understanding of the interplay between myocardial fibrosis and left ventricular function in rheumatic mitral stenosis emerges, underscoring the importance of advanced imaging techniques and the need for ongoing research in this critical area of cardiology.

LITERATURE REVIEW

The article titled "Impairment of Excitation-Contraction Coupling in Right Ventricular Hypertrophied Muscle with Fibrosis Induced by Pulmonary Artery Banding" by (Kusakari et al., 2007) provides a detailed examination of the implications of myocardial fibrosis on cardiac function, particularly in the context of hypertrophy resulting from pressure overload. The authors effectively establish a connection between interstitial cardiac fibrosis and its consequences on excitation-contraction (E-C) coupling, which is critical for maintaining proper cardiac function.

The study begins by highlighting that interstitial cardiac fibrosis is a common sequel of myocardial hypertrophy, particularly in patients suffering from pressure overload due to conditions such as hypertension and valvular heart diseases. This is particularly relevant in the context of rheumatic mitral stenosis, where the pressure overload can lead to significant alterations in myocardial structure and function. The authors argue that excess fibrosis contributes to increased ventricular wall stiffness, which is a key factor in the development of diastolic dysfunction. This assertion aligns with the understanding that diastolic dysfunction is a prevalent issue in patients with heart failure, further emphasizing the clinical importance of the findings.

(Kusakari et al., 2007) delve into the mechanics of E-C coupling, asserting that impaired E-C coupling is a significant contributor to cardiac dysfunction in hypertrophied hearts. The authors present evidence suggesting that myocardial fibrosis may restrict the motion of myocytes, thereby negatively impacting overall cardiac performance. This relationship is crucial, as it underscores the multifaceted nature of cardiac dysfunction where both structural (fibrosis) and functional (E-C coupling) components interact to exacerbate heart failure.

Despite the thorough investigation, the study leaves some questions unanswered, particularly regarding the specific mechanisms through which fibrosis affects E-C coupling in a hypertrophied myocardium. The authors acknowledge that further research is needed to elucidate these mechanisms, which could provide deeper insights into therapeutic strategies for managing conditions characterized by myocardial hypertrophy and fibrosis.

The article titled "The Prognostic Role of Late Gadolinium Enhancement in Aortic Stenosis: A Systematic Review and Meta-Analysis" by (Papanastasiou et al., 2000) provides valuable insights into the role of late gadolinium enhancement (LGE) in the evaluation of myocardial fibrosis, particularly in the context of aortic stenosis (AS). The authors systematically reviewed existing literature to establish a correlation between focal myocardial fibrosis assessed via LGE-CMR and all-cause mortality in patients with AS.

One of the key findings of the study is the significant association between the presence of myocardial fibrosis and adverse outcomes in AS patients. This highlights the importance of LGE-CMR as a diagnostic tool that can provide critical prognostic information. The systematic review encompassed various studies that collectively suggest that myocardial fibrosis, as detected by LGE, is not merely a marker of structural heart disease but also a predictor of clinical outcomes.

The methodology employed in the review is robust, as it synthesizes data from multiple studies, thereby enhancing the reliability of the conclusions drawn. The inclusion criteria for studies, along with the statistical analyses performed, are well articulated, allowing for a clear understanding of how the authors arrived at their conclusions. However, while the article effectively emphasizes the prognostic implications of myocardial fibrosis in AS, it does not delve deeply into the mechanisms by which fibrosis affects left ventricular function, particularly in the context of rheumatic mitral stenosis (MS). This omission may limit the applicability of the findings to other forms of valvular heart disease, such as MS, where the pathophysiological processes may differ.

Additionally, the article could benefit from a discussion on the potential therapeutic implications of detecting myocardial fibrosis in AS patients. Understanding whether interventions aimed at reducing fibrosis could improve outcomes would be a valuable addition to the discourse.

The article "Association Between Left Ventricular Mechanical Deformation and Myocardial Fibrosis in Nonischemic Cardiomyopathy" by (Csecs et al., 2000) presents a comprehensive examination of the interplay between myocardial fibrosis and left ventricular function, particularly in the context of rheumatic mitral stenosis.

The authors elucidate that myocardial fibrosis significantly impairs left ventricular function, a crucial finding for understanding the pathophysiology of various cardiac conditions, including rheumatic heart disease.

The study employs advanced cardiac magnetic resonance (CMR) imaging techniques, specifically feature tracking of cine images, to quantitatively assess left ventricular deformation. This methodology allows for the identification of myocardial scar segments, which is essential in evaluating the extent of fibrosis and its impact on cardiac mechanics. The findings underscore the importance of CMR in providing detailed insights into the structural and functional abnormalities present in patients with advanced heart failure, which often necessitates transplantation.

Moreover, the article highlights the prognostic significance of late gadolinium enhancement (LGE) in nonischemic cardiomyopathy. The authors argue that LGE serves as a critical tool for risk stratification, offering valuable prognostic information that can influence clinical decision-making. This aspect is particularly relevant for patients with rheumatic mitral stenosis, where understanding the degree of myocardial fibrosis can aid in predicting outcomes and tailoring therapeutic strategies.

The authors also discuss the correlation between left ventricular mechanical deformation and the presence of myocardial fibrosis, suggesting that impaired deformation is a direct consequence of fibrotic changes. This relationship is pivotal for clinicians as it provides a tangible metric for assessing cardiac function and guiding management in affected patients.

The article "Novel Approaches in Cardiac Imaging for Non-invasive Assessment of Left Heart Myocardial Fibrosis" by (Elena Mandoli et al., 2001) provides a comprehensive overview of advancements in cardiac imaging techniques that facilitate the non-invasive assessment of myocardial fibrosis (MF), particularly in the context of left heart conditions. The authors highlight the historical recognition of MF as a significant contributor to various cardiac pathologies, tracing its acknowledgment back to the early 1930s. This historical perspective underscores the long-standing importance of understanding MF in clinical settings.

A critical aspect of the article is the discussion on the evolution of imaging technologies, particularly the role of ultrasound and the innovative STE (Speckle Tracking Echocardiography) technique. The authors note that these advancements have improved the sensitivity and reproducibility of detecting myocardial fibrosis, which is crucial for accurate diagnosis and management of patients with cardiac conditions such as rheumatic mitral stenosis. The introduction of LGE (Late Gadolinium Enhancement) CMR (Cardiac Magnetic Resonance) is particularly emphasized for its capability to reliably identify and quantify focal MF. This specificity is vital for clinicians as it allows for targeted therapies and more informed prognostic assessments.

Moreover, the article delves into the potential of CMR mapping techniques to investigate diffuse interstitial fibrosis, which is often more challenging to detect. However, the authors also point out a significant limitation: the absence of disease-specific cut-off values for these imaging modalities. This gap hinders their widespread application in clinical decision-making algorithms, as clinicians require standardized metrics to guide treatment options effectively. The call for future studies to establish reliable cut-off values for STE and CMR parameters is a crucial recommendation that could enhance the utility of these imaging techniques in clinical practice.

The article titled "Predictive Value of Echocardiographic Strain for Myocardial Fibrosis and Adverse Outcomes in Autoimmune Diseases" by (Jia et al., 2002) delves into the significant role of myocardial fibrosis as a pathophysiological mechanism contributing to cardiac complications and increased mortality in patients with autoimmune diseases. This study is particularly relevant to understanding the broader implications of myocardial fibrosis on cardiac function, including its effects in conditions such as rheumatic mitral stenosis.

The authors aim to elucidate the relationship between myocardial strain, measured via speckle-tracking echocardiography (STE), and myocardial fibrosis as assessed through cardiovascular magnetic resonance (CMR). This dual approach not only enhances the understanding of myocardial mechanics but also provides a more comprehensive evaluation of cardiac health in patients suffering from autoimmune

diseases. The findings indicate a clear association between reduced myocardial strain and the presence of fibrosis, suggesting that echocardiographic strain can serve as a valuable predictive tool for identifying myocardial abnormalities.

A critical evaluation of the article reveals several strengths. Firstly, the use of advanced imaging techniques such as STE and CMR allows for a robust assessment of myocardial function and structure, which is essential in identifying subtle changes that may not be evident through conventional echocardiography. Furthermore, the study's focus on the prognostic implications of these findings highlights the potential for early intervention in patients at risk of adverse outcomes due to myocardial fibrosis.

However, the study does have limitations that warrant discussion. The sample size and specific patient demographics may limit the generalizability of the findings. Additionally, while the association between strain and fibrosis is well established, the causal relationship remains to be fully elucidated. Future studies could benefit from a longitudinal design to track changes over time and assess the impact of therapeutic interventions on myocardial strain and fibrosis.

The article titled "Cardiovascular magnetic resonance characterization of rheumatic mitral stenosis: findings from three worldwide endemic zones" by (K. Vidula et al., 2002) provides a comprehensive examination of the impact of rheumatic heart disease on the structural and functional changes in the heart, particularly focusing on mitral stenosis (MS). The authors emphasize that rheumatic heart disease is a predominant cause of MS, which can lead to a cascade of cardiovascular complications, including atrial arrhythmias, pulmonary hypertension, and heart failure.

One of the key insights presented in the article is the notion that while the left ventricle (LV) has historically been perceived as relatively unaffected by the adverse hemodynamic effects of MS, emerging evidence suggests that LV dysfunction can indeed occur in these patients. This challenges the traditional understanding of the disease and underscores the importance of comprehensive cardiac evaluation. The authors argue that progressive MS leads to significant remodeling of cardiac structures, particularly the left atrium (LA), which can

become enlarged and dysfunctional, and can also result in right ventricular (RV) dilation and dysfunction.

The utilization of cardiovascular magnetic resonance (CMR) imaging is highlighted as a critical tool in this context. The authors detail how CMR allows for precise quantification of chamber size and function, as well as tissue characterization through late gadolinium enhancement (LGE) imaging. This capability is particularly important for guiding clinical decisions regarding the timing of interventions and follow-up screenings in patients with rheumatic MS. The article notes that while CMR studies in this patient population have been limited, the findings presented provide valuable insights into the structural and functional changes associated with rheumatic MS.

In critically evaluating the material, it is evident that the authors effectively communicate the significance of CMR in understanding the complexities of cardiac function in patients with rheumatic MS. However, the study could benefit from a larger sample size and a more diverse patient demographic to enhance the generalizability of the findings. Additionally, while the article provides a solid foundation for understanding the implications of LV dysfunction in MS, further research is warranted to explore the underlying mechanisms and potential therapeutic interventions that could mitigate these effects.

The article "Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target" by (Schimmel et al., 2002) provides significant insights into the relationship between myocardial fibrosis and left ventricular (LV) function, particularly in the context of pressure overload conditions. The authors present a compelling argument that the degree of fibrosis is inversely correlated with LV functional improvement, highlighting its critical role as a prognostic factor in heart failure (HF) scenarios.

One of the key findings of the study is the direct association between the extent of fibrosis and all-cause mortality following surgical interventions, such as aortic valve replacement. This suggests that myocardial fibrosis not only serves as a marker for assessing LV function but also has profound implications for clinical outcomes. The authors assert that reactive fibrosis in the LV is a significant

prognostic indicator in HF, which underscores the necessity of addressing myocardial fibrosis in therapeutic strategies aimed at improving patient outcomes. Moreover, the article raises an important point regarding the need to further investigate the contributions of reactive fibrosis to the progression of heart failure. While the authors acknowledge that fibrosis is a critical factor, they also emphasize that other key players may influence LV function. This highlights a gap in the current understanding of myocardial remodeling and its multifaceted nature in the context of rheumatic mitral stenosis and other cardiac conditions.

The study's findings suggest that therapeutic targets aimed at reducing myocardial fibrosis could enhance LV function and improve long-term recovery in patients undergoing surgical treatment. However, the authors call for more comprehensive research to delineate the precise mechanisms by which fibrosis interacts with other pathophysiological processes affecting LV performance.

The article titled "A systematic review of micro-RNAs in aortic stenosis and cardiac fibrosis" by (Osekafore Adewuyi et al., 2002) provides a comprehensive examination of the relationship between myocardial fibrosis, particularly in the context of aortic stenosis (AS), and its implications for cardiac function. The authors effectively highlight the significance of myocardial fibrosis as a pathological entity that can precipitate diastolic dysfunction and potentially lead to heart failure in patients suffering from AS.

A key point in the article is the differentiation between diffuse interstitial fibrosis and replacement fibrosis, both of which can be identified through advanced cardiovascular magnetic resonance imaging (MRI) techniques. This distinction is crucial as it underscores the varying impacts that different types of fibrosis can have on myocardial function. The authors note that focal fibrosis can be present in up to 50% of asymptomatic patients with AS, which raises important clinical considerations regarding the monitoring and management of these patients. The persistence of focal fibrosis as a predictor of mortality even post-surgical intervention is particularly noteworthy, indicating that surgical correction of the stenosis may not fully mitigate the risks associated with pre-existing myocardial fibrosis.

Moreover, the article delves into the molecular mechanisms underlying myocardial fibrosis, specifically the role of micro-RNAs (miRs). The authors present evidence of a correlation between altered levels of miRs and the development of myocardial fibrosis in cardiac diseases. The identification of increased pro-fibrotic miRs and decreased anti-fibrotic miRs in patients with AS provides insight into potential therapeutic targets. The association of specific miRs with diastolic dysfunction and reduced cardiac output suggests that these molecular markers could serve not only as prognostic indicators but also as avenues for future research into targeted therapies.

The article "Impact of Rheumatic Process in Left and Right Ventricular Function in Patients with Mitral Regurgitation" by (Rudiktyo et al., 2003) addresses a critical aspect of rheumatic heart disease (RHD) and its implications for left ventricular (LV) function, particularly in the context of mitral regurgitation (MR). The authors emphasize the high prevalence of RHD in middle- and low-income countries and the significant impact it has on patients, especially those in their productive years. This demographic focus underscores the urgent need for effective healthcare strategies to manage RHD.

The main thrust of the article is the relationship between volume overload due to MR and the subsequent compensatory adaptations of the LV. The authors detail how, over time, these adaptations can lead to LV dysfunction, highlighting a critical transition from a compensated to a decompensated state. This transition is particularly concerning, as it can result in significant morbidity and mortality among affected individuals. The article effectively synthesizes existing literature, including findings from magnetic resonance imaging (MRI) studies, which have demonstrated myocardial fibrosis in patients with rheumatic mitral stenosis. This fibrosis is linked to an inflammatory process that may adversely affect ventricular function.

A noteworthy contribution of this study is its focus on the inflammatory mechanisms underlying myocardial fibrosis in the context of RHD. The presence of Aschoff nodules, indicative of myocardial involvement during acute rheumatic fever (ARF), provides a pathological basis for understanding how chronic

inflammation can lead to structural changes in the myocardium. The authors argue that recognizing the association between inflammation, myocardial fibrosis, and LV dysfunction in chronic MR is vital for improving patient outcomes.

However, while the article presents compelling evidence regarding the impact of MR on LV function, it could benefit from a more detailed exploration of the potential therapeutic interventions that could mitigate these effects. The discussion primarily revolves around the pathophysiological aspects, yet insights into management strategies or future research directions could enhance the practical applicability of the findings.

CONCLUSION

The literature review presents a comprehensive analysis of the interplay between myocardial fibrosis and left ventricular function in patients with rheumatic mitral stenosis, emphasizing the critical role of advanced cardiac imaging techniques, particularly cardiac magnetic resonance (CMR). The introduction establishes the foundation for understanding this complex relationship, highlighting key studies that elucidate the detrimental effects of myocardial fibrosis on cardiac mechanics, particularly in the context of pressure overload and valvular heart disease.

The review draws on various articles that collectively affirm the prognostic significance of myocardial fibrosis, as assessed through late gadolinium enhancement (LGE) and other imaging modalities. For instance, the study by (Kusakari et al., 2007) illustrates how interstitial cardiac fibrosis leads to diastolic dysfunction by increasing ventricular wall stiffness, a finding that is particularly relevant in rheumatic mitral stenosis where chronic pressure overload is common. Furthermore, the systematic review by (Papanastasiou et al., 2000) reinforces the notion that myocardial fibrosis serves as a crucial predictor of adverse clinical outcomes, thereby underscoring the importance of effective imaging techniques for assessing cardiac remodeling.

The analysis of the articles reveals a consistent theme: myocardial fibrosis significantly impairs left ventricular function, which is further substantiated by studies employing advanced imaging techniques. For instance, the work by (Csecs et al., 2000) demonstrates the utility of CMR in quantifying left ventricular

deformation and its correlation with the presence of myocardial fibrosis. This relationship is pivotal for clinicians as it provides tangible metrics for assessing cardiac function and guiding management.

Moreover, the review highlights the evolving landscape of cardiac imaging, as discussed in (Elena Mandoli et al., 2001), which emphasizes the advancements that enhance sensitivity in detecting myocardial fibrosis. The potential for targeted therapies based on imaging findings is a critical aspect that could improve patient outcomes, particularly in the context of rheumatic heart disease.

In conclusion, the literature underscores the significant impact of myocardial fibrosis on left ventricular function in rheumatic mitral stenosis, highlighting the necessity for advanced imaging techniques to accurately assess and manage this condition. The collective findings from various studies reinforce the importance of ongoing research to further elucidate the mechanisms by which myocardial fibrosis affects cardiac function and to explore therapeutic interventions aimed at mitigating its adverse effects.

REFERENCES

- Kusakari, Y., Urashima, T., Shimura, D., Amemiya, E., Miyasaka, G., Yokota, S., Fujimoto, Y., Akaike, T., Inoue, T., & Minamisawa, S., 2007. Impairment of Excitation-Contraction Coupling in Right Ventricular Hypertrophied Muscle with Fibrosis Induced by Pulmonary Artery Banding.
- Papanastasiou, C. A., Kokkinidis, D. G., Kampaktsis, P. N., Bikakis, I., Cunha, D. K., Oikonomou, E. K., Greenwood, J. P., Garcia, M. J., & Karamitsos, T. D., 2000. The Prognostic Role of Late Gadolinium Enhancement in Aortic Stenosis: A Systematic Review and Meta-Analysis.
- Csecs, I., Pashakhanloo, F., Paskavitz, A., Jang, J., Al-Otaibi, T., Neisius, U., J. Manning, W., & Nezafat, R., 2000. Association Between Left Ventricular Mechanical Deformation and Myocardial Fibrosis in Nonischemic Cardiomyopathy.
- Elena Mandoli, G., D'Ascenzi, F., Vinco, G., Benfari, G., Ricci, F., Focardi, M., Cavigli, L., Concetta Pastore, M., Sisti, N., De Vivo, O., Santoro, C., Mondillo, S.,

& Cameli, M., 2001. Novel Approaches in Cardiac Imaging for Non-invasive Assessment of Left Heart Myocardial Fibrosis.

K. Vidula, M., Xu, Z., Xu, Y., Alturki, A., N. Reddy, B., Kini, P., L. Alberto-Delgado, A., Jacob, R., Chen, T., A. Ferrari, V., M. Sierra-Galan, L., Chen, Y., Viswamitra, S., & Han, Y., 2002. Cardiovascular magnetic resonance characterization of rheumatic mitral stenosis: findings from three worldwide endemic zones.

Jia, F., Li, X., Zhang, D., Jiang, S., Yin, J., Feng, X., Zhu, Y., Liu, Y., Zhu, Y., Lai, J., Yang, H., Fang, L., Chen, W., & Wang, Y., 2002. Predictive Value of Echocardiographic Strain for Myocardial Fibrosis and Adverse Outcomes in Autoimmune Diseases.

Schimmel, K., Ichimura, K., Reddy, S., Haddad, F., & Spiekerkoetter, E., 2002. Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target.

Osekafore Adewuyi, J., Patel, R., Abbasciano, R., McCann, G. P., Murphy, G., J. Woźniak, M., & Singh, A., 2002. A systematic review of micro-RNAs in aortic stenosis and cardiac fibrosis.

Rudiktyo, E., Yonas, E., J. Cramer, M., B. Siswanto, B., A. Doevendans, P., & M. Soesanto, A., 2003. Impact of Rheumatic Process in Left and Right Ventricular Function in Patients with Mitral Regurgitation.